Summary
This study was designed to compare the effects of semotiadil, a novel calcium antagonist, with those of diltiazem on the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Pulmonary hypertension was induced by a single injection of monocrotaline (80 mg/kg). Twenty-four hours later (day 1), oral administration of semotiadil (10, 30, or 100 mg/kg per day) or diltiazem (100 or 300 mg/kg per day) was initiated. The wall thickness of the right ventricle (RV), the RV myocardial fiber diameter, the percent medial pulmonary artery thickness, and the percent area of smooth muscle in pulmonary arteries were determined on day 28. The magnitude of all parameters was significantly less in the group of seven rats that received semotiadil at 100 mg/kg per day than in the group of seven rats treated with diltiazem at 300 mg/kg per day. Semotiadil at 100 mg/kg per day inhibits the development of RV hypertrophy and medial thickening of pulmonary arteries significantly more effectively than diltiazem at 300 mg/kg per day.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study.Am J Med 1951;11:686–705.
Grossman W, Braunwald E. Pulmonary hypertension. In: Braunwald E, ed.Heart Disease. Philadelphia: WB Saunders, 1992:790–816.
Kambara H, Fujimoto K, Wakabayashi A, et al. Primary pulmonary hypertension: Beneficial therapy with diltiazem.Am Heart J 1981;101:230–231.
Young TE, Lundquist BS, Chesler E, et al. Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension.Am J Cardiol 1983;51:195–200.
Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.N Engl J Med 1992;327:76–81.
Miyawaki N, Furuta T, Shigei T, et al. Electrophysiological properties of SD-3211, a novel putative Ca2+ antagonist, in isolated guinea pig and rabbit hearts.J Cardiovasc Pharmacol 1990;16:769–775.
Miyawaki N, Furuta T, Shigei T, et al. Cardiovascular characterization of SD-3211, a novel benzothiazine calcium channel blocker, in isolated rabbit hearts.Life Sci 1991;48:1903–1909.
Nishimura K, Miyawaki N, Yamauchi H, et al. Tissue selectivity of the novel calcium antagonist sesamodil fumarate in isolated smooth muscles and cardiac muscles.Arzneim Forsch 1990;40:244–248.
Takada T, Miyawaki N, Kageyama M, et al. Antihypertensive effect of a novel calcium antagonist, SD-3211, in experimental hypertensive rats.J Cardiovasc Pharmacol 1991;18:855–862.
Meyrick B, Reid L. Development of pulmonary arterial changes in rats fedCrotalaria spectabilis. Am J Pathol 1979;94:37–50.
Cassis LA, Rippetoe PE, Soltis EE, et al. Angiotensin II and monocrotaline-induced pulmonary hypertension: Effect of Losartan (Dup 753), a nonpeptide angiotensin type 1 receptor antagonist.J Pharmacol Exp Ther 1992;262:1168–1172.
Meyrick B, Gamble W, Reid L. Development of Crotalaria pulmonary hypertension: Hemodynamic and structural study.Am J Physiol 1980;239:H692-H702.
Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.Circulation 1987;76:135–141.
Pearl RG, Finn JC. Hemodynamic effects of diltiazem during vasoconstrictor pulmonary hypertension in sheep.Anesth Analg 1990;71:493–497.
Reeves WC, Wood MA, Whitesell L, et al. Effect of diltiazem and ibuprofen on right ventricular hypertrophy in an experimental model of hypoxic pulmonary hypertension.Am J Cardiol 1985;56:470–472.
Stanbrook HS, Morris KG, McMurtry IF. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists.Am Rev Respir Dis 1984;130:81–85.
Senda Y, Tohkai H, Kimura M, et al. ECG-gated cardiac scan and echocardiographic assessments of left ventricular hypertrophy: Reversal by 6-month treatment with diltiazem.J Cardiovasc Pharmacol 1990;16:298–304.
Singh BN, Baky S, Nademanee K. Second-generation calcium antagonists: Search for greater selectivity and versatility.Am J Cardiol 1985;55:214B-221B.
Taira N. Differences in cardiovascular profile among calcium antagonists.Am J Cardiol 1987;59:24B-29B.
Kageyama M, Nishimura K, Takada T, et al. SD-3211, a novel benzothiazine calcium antagonist, alone and in combination with a beta-adrenoceptor antagonist, produces antihypertensive effects without affecting heart rate and atrioventricular conduction in conscious renal hypertensive dogs.J Cardiovasc Pharmacol 1991;17:102–107.
Wilson DW, Segall HJ, Pan LC, et al. Mechanisms and pathology of monocrotaline pulmonary toxicity.Crit Rev Toxicol 1992;22:307–325.
Yang Z, Noll G, Lüscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor.Circulation 1993;88:832–836.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takahashi, T., Kanda, T., Imai, S. et al. Semotiadil inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Cardiovasc Drug Ther 9, 809–814 (1995). https://doi.org/10.1007/BF00879875
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00879875